Redhill Biopharma Ltd (RDHL) Stock Analysis
Verdict: AVOID
An $18M upfront Talicia divestment extends cash runway, but a 96.4% revenue crash to $286k in 2025 and $19.22M current liabilities make RDHL highly speculative.
Investment score: 30/100
Analysis as of
Is Redhill Biopharma Ltd stock worth reviewing? AI model thesis
Redhill Biopharma secured a vital $18M cash infusion by selling Talicia to Apotex, but structural cash burn, debt overhang, and 2025 revenue collapse make the shares an extreme micro-cap speculation.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Redhill Biopharma Ltd opportunities and risks
What speaks for RDHL
- $18M Upfront Cash Infusion from Talicia Sale
What speaks against RDHL
- Severe Revenue Collapse and Current Balance Sheet Deficit
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RDHL | n/a | 0.7x | 0.0x | 60.6% | -101.3% | -177.4% |
| INNO.CN | n/a | 0.3x | n/a | 89.8% | -6.0% | -4.8% |
| SPRC | n/a | 0.4x | 0.5x | 46.4% | -1422.8% | -1078.8% |
| PRFX | n/a | 3.0x | 0.4x | -311.8% | -33000.0% | -9019.5% |
| Peer median | n/a | 0.4x | 0.4x | 46.4% | -1422.8% | -1078.8% |
Frequently asked questions about Redhill Biopharma Ltd (RDHL)
Is RDHL stock a good investment?
The cached TradeMates AI model rates Redhill Biopharma Ltd as AVOID with an investment score of 30/100. Redhill Biopharma secured a vital $18M cash infusion by selling Talicia to Apotex, but structural cash burn, debt overhang, and 2025 revenue collapse make the shares an extreme micro-cap speculation. This is algorithmic model output, not personal investment advice.
Is RDHL stock a buy?
The TradeMates model verdict for RDHL is AVOID with an investment score of 30/100. Treat this as a model signal to review, not a personal buy recommendation.